Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. - Wikidata - awgldk - TriplyDB

Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice.

Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice.

http://www.wikidata.org/entity/Q30366836

about

Advances in aluminum hydroxide-based adjuvant research and its mechanism Use of praziquantel as an adjuvant enhances protection and Tc-17 responses to killed H5N1 virus vaccine in mice The Immunomodulatory Role of Adjuvants in Vaccines Formulated with the Recombinant Antigens Ov-103 and Ov-RAL-2 against Onchocerca volvulus in Mice CAF01 potentiates immune responses and efficacy of an inactivated influenza vaccine in ferrets A synthetic adjuvant to enhance and expand immune responses to influenza vaccines Preclinical evaluation of Vaxfectin-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccines Molecular and cellular signatures of human vaccine adjuvants.Development of a vaccine against pandemic influenza viruses: current status and perspectives.Emulsion-based adjuvants for influenza vaccines.An adjuvant for the induction of potent, protective humoral responses to an H5N1 influenza virus vaccine with antigen-sparing effect in mice.MF59 adjuvant: the best insurance against influenza strain diversity.New strategies for the development of H5N1 subtype influenza vaccines: progress and challenges.Protection against intestinal amebiasis by a recombinant vaccine is transferable by T cells and mediated by gamma interferon.The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen.A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge Monocyte-derived dendritic cells promote T follicular helper cell differentiation.The TLR2 Binding Neisserial Porin PorB Enhances Antigen Presenting Cell Trafficking and Cross-presentation.In vitro analysis of acetalated dextran microparticles as a potent delivery platform for vaccine adjuvants.Recent progress in adjuvant discovery for peptide-based subunit vaccines Vaccine development in Staphylococcus aureus: taking the biofilm phenotype into consideration.Describing the hexapeptide identity platform between the influenza A H5N1 and Homo sapiens proteomes.Inflammasome-independent role of the apoptosis-associated speck-like protein containing CARD (ASC) in the adjuvant effect of MF59.The two-component adjuvant IC31® boosts type i interferon production of human monocyte-derived dendritic cells via ligation of endosomal TLRs.Differential effects of viral vectors on migratory afferent lymph dendritic cells in vitro predict enhanced immunogenicity in vivo.Vaccine Potentiation by Combination Adjuvants Immunosenescence and Challenges of Vaccination against Influenza in the Aging Population.Adjuvants for Leishmania vaccines: from models to clinical application.Intranasal Immunization Using Mannatide as a Novel Adjuvant for an Inactivated Influenza Vaccine and Its Adjuvant Effect Compared with MF59.Pre-erythrocytic malaria vaccines: identifying the targets.Cationic lipid/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone) increases antibody response, cellular immunity, and antigenically drifted protection Single- and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets.Chemical cross-linking of HIV-1 Env for direct TLR7/8 ligand conjugation compromises recognition of conserved antigenic determinants The adjuvant MF59 induces ATP release from muscle that potentiates response to vaccination In vitro responses to avian influenza H5 by human CD4 T cells Innate immune control of nucleic acid-based vaccine immunogenicity.The ABC of clinical and experimental adjuvants--a brief overview.Human influenza vaccines and assessment of immunogenicity.Combination adjuvants: the next generation of adjuvants?Trends in vaccine adjuvants.Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines.

P2860

Q27007659-92813874-A283-489C-96D0-6D2833E83C18 Q27304934-D17C2CA5-71E6-41D4-A4AA-983765774AB5 Q28552440-687145EB-7ED4-4F8E-B327-53AD48FC6F3F Q28741710-1300083B-BC34-40C1-A28B-76A04CA343C8 Q28748680-8D403CED-4512-42E6-9EAA-90DA377C0608 Q30352121-EF79FA9F-89A2-4427-AFEC-820CD7FBE5B9 Q30370898-715D2B10-F8EB-496E-9E92-36007B0E636C Q30373784-0F64F647-FAAD-40FD-B1B9-50A2D6A2A975 Q30375985-E569315D-F283-44D6-B069-1D0ED903B7AC Q30390234-0F126FA1-6D3A-493F-80D9-26B0869DAA81 Q30402018-7036B984-395F-44AE-9A88-18906792DFE2 Q30407424-BD96A894-CFDD-445C-88FD-35CD4D00DEC8 Q30436915-1D20D16B-A054-4DED-B439-3703BF7208E1 Q33451335-3BAC7064-761A-49E2-8B0D-E5B7FBB5112B Q33621078-6EB476CB-0A8B-4AFE-9B01-BC751C1BB2A0 Q33623351-D4C3CD93-FA35-463F-9299-B4AAF5747AD4 Q33673210-1D11604D-349C-4DC4-B882-8A08242BE750 Q33901007-BCFC5C70-0E8B-4090-B644-7D1B1960E046 Q34033780-E139ED64-F9E4-49CE-97BB-A4085236C547 Q34113328-4B28175A-3B2C-40C4-81DB-A5B21CAB657E Q34144218-F1944F4F-81E3-49B8-A944-6FEA504D432F Q34582628-56C27CF3-EF12-4E86-851C-1881A3037D1F Q34584142-46A1DDD7-6F99-4957-A0A7-2ECA6C64364C Q35192675-88015486-8AF0-4D19-943D-E7C0E9A8E690 Q35826767-F55473D8-F355-455C-9170-A545C9517D90 Q35874111-A1358D0E-AF52-4EA1-BB69-47656327F8EF Q36021357-9BD376CC-1FB6-41FC-A5A7-9AA7DF923D96 Q36239573-035EEEEF-1CC1-4348-88D4-9CCB72E8A6E5 Q36644236-D0428D00-0591-4C4C-93BF-39ADBF6278E0 Q37212827-F6671BD1-A38A-4E47-A511-DCBEAAAD8BEF Q37223707-84A5EE16-F5CF-416C-9A48-35E209736835 Q37240218-6C718113-650D-489C-9390-56F5DD56DE47 Q37421379-C6773BEF-3508-48FA-B18E-DD5376E015CC Q37439507-DCEDCF11-F9A1-47AB-8DAF-1DB3C1871D84 Q37559651-4923C990-A7D9-424D-8DFE-B24ACA17BBFC Q37628867-532F1EA1-888E-40CB-A470-60F5DDAC3929 Q37812125-023102BE-786C-4AD0-BC1F-72A6764496D0 Q37821483-C47F6AD2-DCE3-4D2B-B592-E2B5367A170C Q37867107-AB803794-D996-43D0-BC3F-C6CF1FF5F488 Q37873932-425B20DD-D801-402C-AB7B-F2F3C4D06DA3

P2860

Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice.

http://www.wikidata.org/entity/Q30366836

description

2007 nî lūn-bûn

@nan

2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Combination adjuvants for the ...... to influenza vaccine in mice.

@ast

Combination adjuvants for the ...... to influenza vaccine in mice.

@en

type

label

Combination adjuvants for the ...... to influenza vaccine in mice.

@ast

Combination adjuvants for the ...... to influenza vaccine in mice.

@en

prefLabel

Combination adjuvants for the ...... to influenza vaccine in mice.

@ast

Combination adjuvants for the ...... to influenza vaccine in mice.

@en

P1433

Q30366836-7609B59F-BA6A-4078-95EE-8310BFB30451

P1476

Q30366836-2AAA08BF-58FE-4303-9BE0-F2E4928F4F8A

P2093

Q30366836-0701D028-0F50-412F-8EF0-C2D086FF377A

Q30366836-1EE59E0A-09BA-4744-B3BE-1A8345667693

Q30366836-461DD9D3-777C-4701-9A66-7F4803C14E0B

Q30366836-55EA5CB5-4FED-4C83-B4EE-CCC8B36AEE13

Q30366836-56B85CC2-1A97-4216-BF23-99C0D1C0BD42

Q30366836-7893FD50-93E5-4F9F-872E-B2489520D54E

Q30366836-A1FB68C4-9A63-46F6-900C-567D7FD50272

Q30366836-C8506FA5-7B4F-482C-9464-46399FA06776

Q30366836-D66F90C8-9C1F-4BBF-B085-612864C26203

Q30366836-DE6115F4-A3D0-42C0-A1B2-E38179BE4989

P304

Q30366836-3AF17B72-DA9C-48D9-AF3C-76981BA9A29D

P31

Q30366836-A94F33D5-85A9-41A0-9137-2D1C13076AB0

P356

Q30366836-C5A905AF-21C9-4E0C-BE62-47798D0B20C4

P407

Q30366836-B1430358-053B-40E1-8BC4-2947B64426D8

P433

Q30366836-6AE940C6-D875-4C2C-83B5-846E69D07014

P478

Q30366836-9B4AAF1E-6CC0-4C66-A8FB-639777D7C344

P50

Q30366836-1B2535B4-D4E3-48A3-B73B-B672842693EF

Q30366836-2C6C43DA-2AD0-43AF-B30C-C19ED4980562

Q30366836-CF13CB44-E02F-402B-BE50-D1910853AB9F

P577

Q30366836-D1D23012-82B4-4398-83F9-50B1B60956D5

P5875

Q30366836-6820A0B8-8C52-4DB3-9A93-223FE7976AC3

P698

Q30366836-FE12801B-30E2-4D26-8863-F1AEE2CF9276

P921

Q30366836-BB6EAB7E-2DCD-4AD7-AEE3-541F1C527CDC

P356

J.VACCINE.2007.11.054

P1433

P1476

Combination adjuvants for the ...... to influenza vaccine in mice.

@en

P2093

Anne K Hilbert

http://www.w3.org/2001/XMLSchema#string

Barbara C Baudner

http://www.w3.org/2001/XMLSchema#string

Derek T O'Hagan

http://www.w3.org/2001/XMLSchema#string

Giuseppe Del Giudice

http://www.w3.org/2001/XMLSchema#string

Hanno Scheffczik

http://www.w3.org/2001/XMLSchema#string

Ilaria Manini

http://www.w3.org/2001/XMLSchema#string

Jina Kazzaz

http://www.w3.org/2001/XMLSchema#string

Manmohan Singh

http://www.w3.org/2001/XMLSchema#string

Mildred Ugozzoli

http://www.w3.org/2001/XMLSchema#string

Sandra Nuti

http://www.w3.org/2001/XMLSchema#string

P304

552-561

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2007.11.054

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

Emanuele Montomoli

P577

2007-12-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5687734

http://www.w3.org/2001/XMLSchema#string

P698

18162266

http://www.w3.org/2001/XMLSchema#string

P921